CSIMarket
 


Myriad Genetics Inc   (MYGN)
Other Ticker:  
 


Myriad Genetics Inc 's EBITDA Margin by quarter

Trends, Rankings, Statistics



MYGN EBITDA Margin (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Revenue Change 10.57 % 22.7 % 2.34 % 9.88 % 10.57 %
Seq. Revenue Change 2.45 % 4.58 % 1.27 % 1.91 % 13.68 %
Revenue In Millions $196.60 $191.90 $183.50 $181.20 $177.80
EBITDA Margin -8.29 % -24.02 % -55.75 % -18.05 % -28.8 %
EBITDA Margin Total Ranking # # # # #
EBITDA In Millions $-16.30 $-46.10 $-102.30 $-32.70 $-51.20
Y / Y EBITDA Change - - - - -
Seq. EBITDA Change - - - - -


Commenting fourth Quarter 2023 EBITDA Margin
Myriad Genetics Inc Operating Loss of -16 fell compare to Operating Loss of $-46.10 millions a quarter before.

Observing fourth quarter 2023 results within In Vitro & In Vivo Diagnostic Substances industry Myriad Genetics Inc has achieved highest EBITDA Margin. While overall EBITDA Margin ranking remained unchanged compare to previous quarter at no. .
Learn about Operating Margin
MYGN's EBITDA Margin fourth quarter 2023 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall # 0

EBITDA Margin Statistics
High Average Low
97.3 % 27.39 % 4.77 %
(Jun 30 2019)   (Dec 31 2019)




Other EBITDA Margin Profitability Ratios
MYGN's Cumulative EBITDA Margin
In Vitro & In Vivo Diagnostic Substances Industry EBITDA Margin Trends and Statistics
Healthcare Sector EBITDA Margin Statistics
EBITDA Margin Profitability Trends for overall market
MYGN's EBITDA Margin Profitability versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking EBITDA Margin
Lowest Ranking EBITDA Margin
EBITDA Margin Profit Margin for MYGN's Competitors
EBITDA Margin Profit Margin for Myriad Genetics Inc 's Suppliers
EBITDA Margin Profit Margin for MYGN's Customers

You may also want to know
MYGN's Annual Growth Rates MYGN's Profitability Ratios MYGN's Asset Turnover Ratio MYGN's Dividend Growth
MYGN's Roe MYGN's Valuation Ratios MYGN's Financial Strength Ratios MYGN's EBITDA Growth
MYGN's Roa MYGN's Inventory Turnover Ratio MYGN's Growth Rates MYGN's Dividend Comparisons


Companies with similar EBITDA Margin in the quarter ending Dec 31 2023, within In Vitro & In Vivo Diagnostic Substances Industry EBITDA MarginDec 31 2023 MRQ EBITDADec 31 2023 MRQ Revenue




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com